Retinal gene therapy: medicine of the near future (C-100452)

CPD
1
19 April 2021
Volume 22, Issue 1
OCT

The first ocular gene therapy has now been approved for use as a treatment, therefore it is important optometrists have a basic understanding of genetics and gene therapy. This article will help with answering patient queries, managing patients and appropriate referrals.

Domains covered

Communication Clinical practice

Abstract

Not so long ago gene therapy was considered in the realms of science fiction. Remarkable progress has been made in the past 15 years, and the first ocular gene therapy to treat a rare inherited retinal disease called Leber congenital amaurosis due to mutations in the RPE65 gene has now been approved by the National Institute for Health and Care Excellence (NICE) for use as a treatment. The first patients in the UK have undergone this treatment on the NHS. This brings gene therapy firmly into the arena of clinical care, making it important for optometrists to have a basic understanding of genetics and gene therapy. This article will help with answering patient queries, managing patients and appropriate referrals.

Sign in to continue

Forgotten password?
Register

Sign in to view the article

Not a member? Start enjoying the benefits of College membership today. Take a look at what the College can offer you and view our membership categories and rates.

Related further reading

For optometrists working in the evolving area of cataract care, it is important to have an understanding of the different drug regimens available. Kathy Oxtoby reports.

Drusen can be a significant finding, but they aren’t always a harbinger of doom. With new approaches on the horizon, asks Kaye McIntosh, what should optometrists do when drusen are found?

AMD

Kaye McIntosh on managing patients with nystagmus in the consulting room – patience is key in examinations.